Recruiting PHASE4 Respiratory Distress Syndrome, Newborn

New treatment option for Respiratory Distress Syndrome, Newborn

Official title Prophylactic Minimally Invasive Surfactant Evaluation

ClinicalTrials.gov ID: NCT06007547

What this study is testing

What is Poractant Alfa?

Poractant Alfa is an investigational medicine, being studied as a potential treatment for respiratory distress syndrome, newborn.

Also referred to as Minimally Invasive Surfactant Therapy.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?
  • Phase 4: studies an already-approved treatment
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages up to 15. Healthy volunteers may be eligible.

You may be able to join if

  • Gestational age \<30 weeks
  • Antenatal consent from Parent

You likely can't join if

  • Congenital anomalies
  • Alternate cause of respiratory distress

The study team makes the final eligibility decision.

Where it's taking place

  • Evanston, Illinois, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, up to 15 minutes. Healthy volunteers may be eligible. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Evanston, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.